Evidence map›Paper›PMID 30377381›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2019

Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.

William C Hochberger, Yash B Joshi, Michael L Thomas, Wendy Zhang, Andrew W Bismark, Emily B H Treichler, Melissa Tarasenko, John Nungaray, Joyce Sprock, Lauren Cardoso and 2 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Memantine effects on auditory discrimination and training in schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Auditory event-related potentials and psychosis dimensions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Candidate biomarkers in psychiatric disorders: state of the field.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

William C HochbergerDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1557-0105
Yash B JoshiDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Michael L ThomasDepartment of Psychology, Colorado State University, Fort Collins, CO, USA.
Wendy ZhangSan Diego State University/University of California, San Diego (SDSU/UCSD) Joint Doctoral Program (JDP) in Clinical Psychology, San Diego, CA, USA.
Andrew W BismarkDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Emily B H TreichlerDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Melissa TarasenkoDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
John NungarayDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Joyce SprockDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Lauren CardosoDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Neal SwerdlowDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Gregory A LightDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA. glight@ucsd.edu.
University of California San Diego · USSan Diego State University · USColorado State University · US

Funding

Pharmacologic augmentation of neurocognition and cognitive training in psychosisR01MH059803 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 1999 to 2018
$4.5M
Memantine effects on sensorimotor gating and neurocognition in schizophreniaR01MH094320 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2012 to 2020
$2.6M
Neuroimaging and Neurocognitive Computerized Adaptive Testing in SchizophreniaK23MH102420 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI THOMAS, MICHAEL L · 2014 to 2018
$815k
NIMH NIH HHS K23 MH102420NIMH NIH HHS R01 MH059803NIMH NIH HHS R01 MH094320
6 · The paper itself

Abstract

Cognitive impairment is a core feature of schizophrenia and a strong predictor of psychosocial disability. Auditory-based targeted cognitive training (TCT) aims to enhance verbal learning and other domains of cognitive functioning through "bottom-up" tuning of the neural systems underlying early auditory information processing (EAIP). Although TCT has demonstrated efficacy at the group level, individual response to TCT varies considerably, with nearly half of patients showing little-to-no benefit. EEG measures of EAIP, mismatch negativity (MMN) and P3a, are sensitive to the neural systems engaged by TCT exercises and might therefore predict clinical outcomes after a full course of treatment. This study aimed to determine whether initial malleability of MMN and P3a to 1-h of auditory-based TCT predicts improvements in verbal learning and clinical symptom reduction following a full (30-h) course of TCT. Treatment refractory patients diagnosed with schizophrenia were randomly assigned to receive treatment-as-usual (TAU; n = 22) or TAU augmented with TCT (n = 23). Results indicated that malleability (i.e., change from baseline after the initial 1-h dose of TCT) of MMN and P3a predicted improvements in verbal learning as well as decreases in the severity of positive symptoms. Examination of MMN and P3a malleability in patients after their first dose of TCT can be used to predict clinical response to a full course of treatment and shows promise for future biomarker-informed treatment assignment.

Indexed as

Outcome Assessment, Health CareAdultCognitive DysfunctionCognitive RemediationElectroencephalographyEvent-Related Potentials, P300Evoked PotentialsFemaleHumansMaleMiddle AgedPsychotic DisordersSchizophreniaSpeech PerceptionVerbal LearningYoung Adult

Identifiers

PMID30377381
PMCPMC6333927
OpenAlexW2898915570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.